ClinicalTrials.gg
CompletedNCT02771210ACHILLESUpdated May 3, 2021Results posted

Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site

A Phase 3 interventional study of Secukinumab and Secukinumab Placebo in Psoriatic Arthritis, Axial Spondyloarthritis and Enthesitis, sponsored by Novartis Pharmaceuticals. Completed at 55 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-03.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing secukinumab in Arthritis, Psoriatic — 2 open to participants now, 2 under way, 1 of them phase 3. secukinumab · Arthritis, Psoriatic.

Enrollment
14th of 26
204 · median 231
Started
2016
with 4 others
Phase 3
16 of 26
1 open now
Registered
14th of 26
by date
Lead sponsor
17 of 26
Novartis Pharmaceuticals

Among the 26 studies testing secukinumab in Arthritis, Psoriatic, this one is the 14th largest by enrollment, is one of 5 that started in 2016, is one of 16 in phase 3, and was the 14th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

2 of the 26 studies testing secukinumab in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing secukinumab in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

The purpose of this study was to demonstrate efficacy, including effects on inflammation by magnetic resonance imaging (MRI) assessments, of secukinumab on Achilles tendon enthesitis for up to 1 year with a primary focus at Week 24, in patients with active Psoriatic Arthritis and axial Spondyloarthritis despite current or previous non-steroidal anti-inflammatory drugs (NSAID) and/or disease modifying anti-rheumatic drug (DMARD) and/or anti-TNFα therapy.

Read the detailed description

Primary endpoint was at week 24 but there was no interim Clinical Study Report. While Protocol states at chapter 9.7 that a week 24 analysis may be provided (not mandatory as per protocol), all data has been analyzed at week 52.

Some of the secondary endpoints include the whole study period up to week 52 (to address questions on switching placebo to active drug)

03

Conditions studied

  • Psoriatic Arthritis
  • Axial Spondyloarthritis
  • Enthesitis

Keywords

  • Active psoriatic arthritis
  • Axial spondyloarthritides
  • Subcutaneous
  • Secukinumab in prefilled syringe
  • Enthesitis
  • Achilles tendon
  • AxSpA
  • PsA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patients with Psoriatic arthritis: Diagnosis of Psoriatic arthritis as per the Classification criteria for Psoriatic Arthritis (CASPAR criteria) with symptoms for at least 6 months and active Psoriatic arthritis as assessed by ≥ 1 tender joints out of 78 and ≥ 1 swollen joints out of 76 at Baseline (dactylitis of a digit counts as one joint each).
  • Patients with Axial Spondyloarthritis: Diagnosis of Axial Spondyloarthritis as per the classification of the Assessment of Spondyloarthritis International Society axial Spondyloarthritis (ASAS) criteria and objective signs of inflammation at Screening (magnetic resonance imaging (MRI) or definite radiographic sacroilitis and/or abnormal C-Reactive Protein) and active disease assessed by total Bath ankylosing spondylitis disease activity index (BASDAI) ≥ 4 (0-10) at Baseline.
  • Diagnosis of Achilles tendon enthesitis according to swelling and tenderness at the insertional site of the Achilles tendon into the calcaneus.
  • Onset of heel pain ≥ 1 month at Baseline.
  • Heel enthesitis that is magnetic resonance imaging (MRI)-positive according to the investigator's judgement.
  • Patients who have been exposed to up to two TNFα inhibitors.

Key Exclusion Criteria:

  • Chest X-ray or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process.
  • Previous exposure to secukinumab or other biologic drug directly targeting Interleukin (IL)-17 or Interleukin (IL)-17 receptor.
  • Ongoing use of psoriasis treatments / medications (e.g. topical , ultraviolet (UV) therapy) at randomization.
  • Patients who have previously been exposed to more than two Tumor necrosis factor (TNF) inhibitors ( or approved).
  • Patients who have ever received biologic immunomodulating agents (investigational or approved), except those targeting Tumor necrosis factor (TNF) inhibitors.
  • Pregnant or nursing (lactating) women.
  • History of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis infection.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
204 participants (actual)

Study arms

  • Experimental
    AIN457/Secukinumab

    Secukinumab 150 mg s.c. or Secukinumab 300 mg s.c., respective dose was assigned according to underlying condition, in case of PsA according to severity of concomitant Psoriasis or pre-exposure to anti-TNFα

    Biological: Secukinumab

  • Placebo comparator
    AIN457/Secukinumab Placebo

    Secukinumab Placebo s.c.

    Drug: Secukinumab Placebo

Interventions

  • BiologicalSecukinumab

    Induction: Week 0,1,2,3 150 mg or 300 mg Secukinumab s.c. Maintenance: 150 mg or 300 mg Secukinumab s.c. every 4 weeks starting at Week 4

    Also known as: AIN457A

  • DrugSecukinumab Placebo

    Induction: Week 0,1,2,3 Secukinumab Placebo s.c. Maintenance: Secukinumab Placebo s.c. every 4 weeks starting at Week 4 until Week 24 followed by 150 or 300 mg Secukinumab s.c. every 4 weeks

    Also known as: AIN457/Secukinumab Placebo

06

What researchers measure

Primary outcomes

  1. Number (%) of Patients With Resolution of Achilles Tendon Enthesitis

    Number (%) of patients with resolution of Achilles tendon enthesitis (affected foot) as assessed by respective subcomponent of Leeds enthesitis index (LEI) at Week 24. The primary analysis was performed via a logistic regression model with the factors treatment, country, and stratification factor diagnosis (PsA or axSpA); patients with a missing assessment were considered as responders if they had already met the response criterion at the time of last assessment.

    Time frame: Week 24

Secondary outcomes

  1. Mean Change of Heel Pain

    Mean change of heel pain from baseline to Week 24 measured by Numeric Rating Scale (NRS) ranging from 0 to 10, with 0 representing no pain and 10 representing worst pain (e.g. "pain as bad as you can imagine" or "worst pain imaginable").

    Time frame: Week 24

  2. Number (%) of Patients With Improvement of Bone Marrow Edema

    Number (%) of patients with an improvement of bone marrow edema from baseline to Week 24 as assessed by the respective subcomponent of the Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) in the affected foot.

    Time frame: Week 24

  3. Number (%) of Patients With Resolution of Enthesitis as Assessed by LEI

    Number (%) of patients with resolution of enthesitis as assessed by the Leeds enthesitis index (LEI) at Week 24.

    Time frame: Week 24

  4. Mean Change of Physician's Global Assessment of Disease Activity

    Mean change of physician's global assessment (PhGA) of disease activity from baseline to Week 24 measured by Visual Analog Scale (VAS) ranging from 0 to 100, with 0 representing not severe and 100 representing very severe.

    Time frame: Week 24

  5. Mean Change of Patient's Global Assessment of Disease Activity

    Mean change of patient's global assessment (PGA) of disease activity from baseline to Week 24 measured by Visual Analog Scale (VAS) ranging from 0 to 100, with 0 representing not severe and 100 representing very severe.

    Time frame: Week 24

  6. Mean Change of Physician's Assessment of Heel Enthesopathy Activity

    Mean change of physician's assessment of heel enthesopathy activity from baseline to Week 24 measured by Visual Analog Scale (VAS) ranging from 0 to 100, with 0 representing not severe and 100 representing very severe.

    Time frame: Week 24

  7. Mean Change of Patient's Assessment of Heel Enthesopathy Activity

    Mean change of patient's assessment of heel enthesopathy activity from baseline to Week 24 measured by Visual Analog Scale (VAS) ranging from 0 to 100, with 0 representing not severe and 100 representing very severe.

    Time frame: Week 24

  8. Mean Change in Short Form-36 (SF-36) v2

    Mean change in Short Form-36 (SF-36) v2 as an indicator of overall health status The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability

    Time frame: Week 24

  9. Percentage of Patients With Resolution of Achilles Tendon Enthesitis After Switching From Placebo to Secukinumab

    Percentage of patients with resolution of Achilles tendon enthesitis (affected foot) after switching from placebo to secukinumab at Week 24

    Time frame: Weeks 24 and 52

  10. Mean Change of Heel Pain After Switching From Placebo to Secukinumab

    Mean change of heel pain after switching from placebo to secukinumab from Week 24 to week 52 measured by Numeric Rating Scale (NRS) ranging from 0 to 10, with 0 representing no pain and 10 representing worst pain (e.g. "pain as bad as you can imagine" or "worst pain imaginable").

    Time frame: Change from week 24 to week 52

07

Results

Posted Jan 27, 2021

Participant flow

304 patients were screened. Of these, 94 patients discontinued during screening phase, 6 patients were re-screened and 204 patients completed the screening phase and were randomized in the trial.

Period 1
Participant flow — Period 1
MilestoneSecukinumabPlacebo
Started102102
Completed9184
Not completed1118
Withdrew: Adverse event53
Withdrew: Lack of efficacy36
Withdrew: Lost to follow-up20
Withdrew: Physician decision01
Withdrew: Withdrawal by subject03
Withdrew: Withdrawal of informed consent15
Period 2
Participant flow — Period 2
MilestoneSecukinumabPlacebo
Started9184
Completed8981
Not completed23
Withdrew: Adverse event10
Withdrew: Lack of efficacy01
Withdrew: Withdrawal by subject10
Withdrew: Withdrawal of informed consent02

Outcome measures

PrimaryNumber (%) of Patients With Resolution of Achilles Tendon Enthesitis

Number (%) of patients with resolution of Achilles tendon enthesitis (affected foot) as assessed by respective subcomponent of Leeds enthesitis index (LEI) at Week 24. The primary analysis was performed via a logistic regression model with the factors treatment, country, and stratification factor diagnosis (PsA or axSpA); patients with a missing assessment were considered as responders if they had already met the response criterion at the time of last assessment.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number (%) of Patients With Resolution of Achilles Tendon Enthesitis
ParticipantsSecukinumabPlacebo
Number (%) of Patients With Resolution of Achilles Tendon Enthesitis4332
Statistical analysis
  • Secukinumab vs Placebo · Regression, Logistic · p = 0.136 · Odds ratio (or): 1.63 · 95% CI 0.87 to 3.08
SecondaryMean Change of Heel Pain

Mean change of heel pain from baseline to Week 24 measured by Numeric Rating Scale (NRS) ranging from 0 to 10, with 0 representing no pain and 10 representing worst pain (e.g. "pain as bad as you can imagine" or "worst pain imaginable").

Time frame:
Week 24
Reported as:
Mean · Scores on a scale
Mean Change of Heel Pain
Scores on a scaleSecukinumabPlacebo
Mean Change of Heel Pain-2.8 ± 2.99-1.9 ± 2.69
SecondaryNumber (%) of Patients With Improvement of Bone Marrow Edema

Number (%) of patients with an improvement of bone marrow edema from baseline to Week 24 as assessed by the respective subcomponent of the Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) in the affected foot.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number (%) of Patients With Improvement of Bone Marrow Edema
ParticipantsSecukinumabPlacebo
Number (%) of Patients With Improvement of Bone Marrow Edema1712
SecondaryNumber (%) of Patients With Resolution of Enthesitis as Assessed by LEI

Number (%) of patients with resolution of enthesitis as assessed by the Leeds enthesitis index (LEI) at Week 24.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number (%) of Patients With Resolution of Enthesitis as Assessed by LEI
ParticipantsSecukinumabPlacebo
Number (%) of Patients With Resolution of Enthesitis as Assessed by LEI3121
SecondaryMean Change of Physician's Global Assessment of Disease Activity

Mean change of physician's global assessment (PhGA) of disease activity from baseline to Week 24 measured by Visual Analog Scale (VAS) ranging from 0 to 100, with 0 representing not severe and 100 representing very severe.

Time frame:
Week 24
Reported as:
Mean · mm
Mean Change of Physician's Global Assessment of Disease Activity
mmSecukinumabPlacebo
Mean Change of Physician's Global Assessment of Disease Activity-34.88 ± 25.927-18.93 ± 26.257
SecondaryMean Change of Patient's Global Assessment of Disease Activity

Mean change of patient's global assessment (PGA) of disease activity from baseline to Week 24 measured by Visual Analog Scale (VAS) ranging from 0 to 100, with 0 representing not severe and 100 representing very severe.

Time frame:
Week 24
Reported as:
Mean · mm
Mean Change of Patient's Global Assessment of Disease Activity
mmSecukinumabPlacebo
Mean Change of Patient's Global Assessment of Disease Activity-25.87 ± 31.108-16.61 ± 29.235
SecondaryMean Change of Physician's Assessment of Heel Enthesopathy Activity

Mean change of physician's assessment of heel enthesopathy activity from baseline to Week 24 measured by Visual Analog Scale (VAS) ranging from 0 to 100, with 0 representing not severe and 100 representing very severe.

Time frame:
Week 24
Reported as:
Mean · mm
Mean Change of Physician's Assessment of Heel Enthesopathy Activity
mmSecukinumabPlacebo
Mean Change of Physician's Assessment of Heel Enthesopathy Activity-38.40 ± 24.244-25.19 ± 25.250
SecondaryMean Change of Patient's Assessment of Heel Enthesopathy Activity

Mean change of patient's assessment of heel enthesopathy activity from baseline to Week 24 measured by Visual Analog Scale (VAS) ranging from 0 to 100, with 0 representing not severe and 100 representing very severe.

Time frame:
Week 24
Reported as:
Mean · mm
Mean Change of Patient's Assessment of Heel Enthesopathy Activity
mmSecukinumabPlacebo
Mean Change of Patient's Assessment of Heel Enthesopathy Activity-31.05 ± 29.135-20.77 ± 30.417
SecondaryMean Change in Short Form-36 (SF-36) v2

Mean change in Short Form-36 (SF-36) v2 as an indicator of overall health status The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability

Time frame:
Week 24
Reported as:
Mean · scores on a scale
Mean Change in Short Form-36 (SF-36) v2
scores on a scaleSecukinumabPlacebo
Mean Change in Short Form-36 (SF-36) v28.29 ± 9.7595.28 ± 7.285
SecondaryPercentage of Patients With Resolution of Achilles Tendon Enthesitis After Switching From Placebo to Secukinumab

Percentage of patients with resolution of Achilles tendon enthesitis (affected foot) after switching from placebo to secukinumab at Week 24

Time frame:
Weeks 24 and 52
Reported as:
Count of participants · Participants
Percentage of Patients With Resolution of Achilles Tendon Enthesitis After Switching From Placebo to Secukinumab
ParticipantsSecukinumabPlacebo
Week 244332
Week 526655
SecondaryMean Change of Heel Pain After Switching From Placebo to Secukinumab

Mean change of heel pain after switching from placebo to secukinumab from Week 24 to week 52 measured by Numeric Rating Scale (NRS) ranging from 0 to 10, with 0 representing no pain and 10 representing worst pain (e.g. "pain as bad as you can imagine" or "worst pain imaginable").

Time frame:
Change from week 24 to week 52
Reported as:
Mean · Scores on a scale
Mean Change of Heel Pain After Switching From Placebo to Secukinumab
Scores on a scaleSecukinumabPlacebo
Mean Change of Heel Pain After Switching From Placebo to Secukinumab-0.70 ± 2.291-1.43 ± 2.251

Adverse events

Collected over Adverse events were collected from first dose of study treatment until end of study treatment at week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Secukinumab0/102 (0%)7/102 (6.9%)33/102 (32.4%)
Placebo-Secukinumab0/102 (0%)6/102 (5.9%)34/102 (33.3%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventSecukinumabPlacebo-Secukinumab
Atrial fibrillationCardiac disorders1/1021/102
GoitreEndocrine disorders0/1021/102
Abdominal adhesionsGastrointestinal disorders0/1021/102
Inflammatory bowel diseaseGastrointestinal disorders1/1021/102
Large intestinal stenosisGastrointestinal disorders0/1021/102
CellulitisInfections and infestations1/1020/102
DiverticulitisInfections and infestations0/1021/102
Pyelonephritis acuteInfections and infestations0/1021/102
Lower limb fractureInjury, poisoning and procedural complications0/1021/102
Stress fractureInjury, poisoning and procedural complications0/1021/102
Most frequent other events
Most frequent other events
EventSecukinumabPlacebo-Secukinumab
NasopharyngitisInfections and infestations13/10222/102
HeadacheNervous system disorders6/10210/102
DiarrhoeaGastrointestinal disorders8/1025/102
ArthralgiaMusculoskeletal and connective tissue disorders7/1025/102
Upper respiratory tract infectionInfections and infestations6/1025/102

Baseline characteristics

Randomized Set: The Randomized set was defined as all patients who were randomized. Unless otherwise specified, mis-randomized patients in the IRT were excluded from the randomized set.

Age, Categorical
Age, Categorical(Participants)SecukinumabPlaceboTotal
<=18 years000
Between 18 and 65 years9795192
>=65 years5712
Age, Continuous
Age, Continuous(Years)SecukinumabPlaceboTotal
Mean47.8 ± 11.3347.7 ± 11.0247.7 ± 11.18
Sex/Gender, Customized
Sex/Gender, Customized(Participants)SecukinumabPlaceboTotal
Female5855113
Male444791
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SecukinumabPlaceboTotal
Caucasian9999198
Black000
Asian213
Other123
08

Study locations

55 sites
  • Novartis Investigative Site
    Plovdiv, 4002, Bulgaria
  • Novartis Investigative Site
    Sofia, 1407, Bulgaria
  • Novartis Investigative Site
    Sofia, 1413, Bulgaria
  • Novartis Investigative Site
    Stara Zagora, 6000, Bulgaria
  • Novartis Investigative Site
    Targovishte, 7700, Bulgaria
  • Novartis Investigative Site
    Praha 4, Czech Republic 140 59, Czechia
  • Novartis Investigative Site
    Brno, 63800, Czechia
  • Novartis Investigative Site
    Prague 2, 128 50, Czechia
  • Novartis Investigative Site
    Uherske Hradiste, 686 01, Czechia
  • Novartis Investigative Site
    Berlin, 12435, Germany
  • Novartis Investigative Site
    Berlin, 14059, Germany
  • Novartis Investigative Site
    Cottbus, 03042, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Frankfurt am Main, 60528, Germany
  • Novartis Investigative Site
    Hamburg, 22391, Germany
  • Novartis Investigative Site
    Hamburg, 22415, Germany
  • Novartis Investigative Site
    Hannover, 30161, Germany
  • Novartis Investigative Site
    Herne, 44649, Germany
  • Novartis Investigative Site
    Koeln, 50937, Germany
  • Novartis Investigative Site
    Magdeburg, 39104, Germany
  • Novartis Investigative Site
    Magdeburg, 39110, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Wuppertal, 42105, Germany
  • Novartis Investigative Site
    Athens, 115 21, Greece
  • Novartis Investigative Site
    Athens, 115 27, Greece
  • Novartis Investigative Site
    Heraklion Crete, 711 10, Greece
  • Novartis Investigative Site
    Thessaloniki, 54642, Greece
  • Novartis Investigative Site
    Bergamo, BG 24128, Italy
  • Novartis Investigative Site
    Milano, MI 20100, Italy
  • Novartis Investigative Site
    Potenza, PZ 85100, Italy
  • Novartis Investigative Site
    Torino, TO 10128, Italy
  • Novartis Investigative Site
    Verona, VR 37134, Italy
  • Novartis Investigative Site
    Bologna, 40138, Italy
  • Novartis Investigative Site
    Piestany, 92101, Slovakia
  • Novartis Investigative Site
    Sevilla, Andalucia 41009, Spain
  • Novartis Investigative Site
    Torrelavega, Cantabria 39300, Spain
  • Novartis Investigative Site
    Merida, Extremadura 06800, Spain
  • Novartis Investigative Site
    Orense, Galicia 32005, Spain
  • Novartis Investigative Site
    Santiago de Compostela, Galicia 15706, Spain
  • Novartis Investigative Site
    Cartagena, Murcia 30202, Spain
  • Novartis Investigative Site
    Vigo, Pontevedra 36200, Spain
  • Novartis Investigative Site
    Baracaldo, Vizcaya 48903, Spain
  • Novartis Investigative Site
    Madrid, 28040, Spain
  • Novartis Investigative Site
    Madrid, 28046, Spain
  • Novartis Investigative Site
    Madrid, 28942, Spain
  • Novartis Investigative Site
    Malaga, 29009, Spain
  • Novartis Investigative Site
    Pontevedra, 36001, Spain
  • Novartis Investigative Site
    Truro, Cornwall TR1 3LJ, United Kingdom
  • Novartis Investigative Site
    Leytonstone, London E11 1NR, United Kingdom
  • Novartis Investigative Site
    Stoke on Trent, Staffordshire ST6 7AG, United Kingdom
  • Novartis Investigative Site
    Barnsley, S75 2EP, United Kingdom
  • Novartis Investigative Site
    Cheshire, CW1 4QJ, United Kingdom
  • Novartis Investigative Site
    Hull, HU3 2JZ, United Kingdom
  • Novartis Investigative Site
    London, NW3 2QG, United Kingdom
  • Novartis Investigative Site
    Tyne And Wear, NE29 8NH, United Kingdom
09

References and documents

Publications

  • Baraliakos X, Sewerin P, de Miguel E, Pournara E, Kleinmond C, Shekhawat A, Jentzsch C, Wiedon A, Behrens F; ACHILLES study group. Magnetic resonance imaging characteristics in patients with spondyloarthritis and clinical diagnosis of heel enthesitis: post hoc analysis from the phase 3 ACHILLES trial. Arthritis Res Ther. 2022 May 16;24(1):111. doi: 10.1186/s13075-022-02797-8. PubMed 35578245 ↗
  • Behrens F, Sewerin P, de Miguel E, Patel Y, Batalov A, Dokoupilova E, Kleinmond C, Pournara E, Shekhawat A, Jentzsch C, Wiedon A, Baraliakos X; ACHILLES study group. Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial. Rheumatology (Oxford). 2022 Jul 6;61(7):2856-2866. doi: 10.1093/rheumatology/keab784. PubMed 34730795 ↗
  • Baraliakos X, Sewerin P, de Miguel E, Pournara E, Kleinmond C, Wiedon A, Behrens F. Achilles tendon enthesitis evaluated by MRI assessments in patients with axial spondyloarthritis and psoriatic arthritis: a report of the methodology of the ACHILLES trial. BMC Musculoskelet Disord. 2020 Nov 21;21(1):767. doi: 10.1186/s12891-020-03775-4. PubMed 33220702 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Dec 2019, 39 months.

Results were first posted in Jan 2021, 1 year 1 month after primary completion. A results delay was requested in Mar 2020.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 39 months is above that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2016
First posted
May 13, 2016
StartActual
Aug 30, 2016
Primary completionActual
Dec 11, 2019
CompletionActual
Dec 11, 2019
Results delay requested
Mar 31, 2020
Results first posted
Jan 27, 2021
Last update
May 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02771210
Responsible party
Sponsor
First posted
May 13, 2016
Start date
Aug 30, 2016
Primary completion
Dec 11, 2019
Completion
Dec 11, 2019
Results posted
Jan 27, 2021
Last update
May 3, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion